Stockholders' equity (deficit)
|
6 Months Ended | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2014
|
||||||||||||||||||||||||||
Notes to Financial Statements | ||||||||||||||||||||||||||
Stockholders' equity |
Preferred Stock The Company has authorized up to 5,000,000 shares of preferred stock, $0.001 par value per share, for issuance. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Companys board of directors upon its issuance. In connection with the Merger Agreement, the Company issued to Cocrystal Discoverys security holders 1,000,000 shares of the Companys Series B Convertible Preferred Stock (Series B). The Series B shares: (i) automatically convert into shares of the Companys common stock at a rate of 205.08308640 shares for each share of Series B at such time that the Company has sufficient authorized capital, (ii) are entitled to vote on all matters submitted to shareholders of the Company and vote on an as converted basis and (iii) have a nominal liquidation preference.
Common Stock The Company has authorized up to 200,000,000 shares of common stock, $0.001 par value per share, for issuance. As noted above, the shares of Series B will automatically convert into shares of the Companys common stock at such time that the Company has sufficient authorized capital. In addition to the 205,083,086 shares issuable upon conversion of the Series B, shares of common stock are reserved for future issuance as follows as of June 30, 2014 (in thousands):
|